Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5074242 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL2239761 | 0.77 | TSHR (0.44) | L3MBTL1KDM4ENPSR1HSD17B10 | |
| SCHEMBL7428953 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL23352009 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL4757619 | 0.76 | GAA (0.53) | SMN1; SMN2GAAALDH1A1TDP1KDM4E | |
| SCHEMBL13116870 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL14421937 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL11039671 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL274448 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2GAAALDH1A1CYP3A4MEN1 | |
| SCHEMBL7358278 | 0.75 | GAA (0.57) | SMN1; SMN2GAAALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | claimed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | claimed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | claimed |
| JP-2001517620-A | — | — | 2001-10-09 | — | — | JP | claimed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | claimed |
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | SMN1; SMN2 3225/4885GAA 746/4885ALDH1A1 1080/4885 |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | SMN1; SMN2 3211/4885GAA 3201/4885ALDH1A1 262/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | SMN1; SMN2 3432/4885GAA 567/4885ALDH1A1 886/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | SMN1; SMN2 2943/4885GAA 710/4885ALDH1A1 385/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | SMN1; SMN2 1509/4885GAA 1003/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.